Skip to content
Comparison

Tesamorelin vs CJC-1295

Tesamorelin and CJC-1295 are both synthetic growth hormone-releasing hormone (GHRH) analogs that stimulate the pituitary to release natural growth hormone. Tesamorelin is FDA-approved (as Egrifta) for HIV-associated lipodystrophy and has the most robust clinical evidence of any GHRH peptide. CJC-1295 (particularly the DAC form) is a longer-acting research peptide with a much longer half-life than native GHRH, making it convenient for less frequent dosing. Tesamorelin has proven clinical efficacy and a safety profile established in rigorous trials; CJC-1295 is widely used in anti-aging and performance contexts but lacks FDA-approved human indication.

4.3(112 ratings)

Quick Answer

Tesamorelin and CJC-1295 are both GHRH analogs that stimulate natural GH release, but they differ in half-life, clinical evidence, and legality. Tesamorelin is FDA-approved (Egrifta for HIV lipodystrophy) with strong clinical trial data — 1–3 mg daily produces 15–30% IGF-1 increases and significant visceral fat reduction. CJC-1295 (DAC form) has a much longer half-life (~6–8 days) enabling weekly dosing, and is widely stacked with ipamorelin. Tesamorelin wins on evidence quality; CJC-1295 wins on dosing convenience.

Head-to-Head Comparison

CriteriaTesamorelinCJC-1295
MechanismModified GHRH(1-44) analog with stabilized N-terminus for GH secretionCJC-1295 (no DAC): modified GHRH(1-29) with 30-min half-life; CJC-1295 DAC: same with Drug Affinity Complex extending half-life to 6–8 days
FDA approvalEgrifta SV — FDA-approved for HIV-associated lipodystrophy (visceral fat reduction)No FDA approval — research/compounding use only
Half-life~26 minutes (requires daily injection)No DAC: ~30 minutes (daily); DAC form: ~6–8 days (weekly dosing possible)
Typical dosing1–2 mg subcutaneous daily, usually before bedNo DAC: 100–200 mcg 1–2× daily; DAC: 1–2 mg once or twice weekly
IGF-1 elevation15–30% increase in Phase 3 lipodystrophy trials~200–300% elevation documented in clinical studies with DAC form (sustained bleed)
Primary clinical evidenceRandomized controlled trials in HIV lipodystrophy — visceral fat reduction, metabolic improvementPhase 1/2 trials showing GH/IGF-1 elevation; no approved indication
Effect on cortisol/prolactinPrimarily GH selective — modest cortisol increase possible at high dosesGenerally selective for GH; DAC form can cause sustained elevated GH baseline
Synergy with GHRPsCommonly combined with ipamorelin in clinical protocols (GHRH + GHRP synergy)Most commonly stacked with ipamorelin (one of the most popular GH stacks)
Visceral fat reductionProven in Phase 3 trials — significant visceral adipose tissue reductionIndirect via GH/IGF-1 elevation; less documented than tesamorelin
Approximate cost (research grade)$80–$200/month (clinic/research); Egrifta list ~$15,000+/month (insurance required)$30–$70/month (research grade, no DAC); $50–$100/month (DAC form)
Compounding availabilityAvailable via compounding pharmacies (FDA-approved reference product)Available via research chemical suppliers and some compounding pharmacies

When to Choose Each

Choose Tesamorelin

HIV-positive patients with lipodystrophy (FDA-approved indication), physician-supervised GH optimization with established clinical evidence, anti-aging patients with documented visceral adiposity who want the most evidence-backed GHRH analog.

Choose CJC-1295

Anti-aging and performance users seeking convenience (weekly dosing with DAC form), those on budget-constrained protocols, CJC-1295/ipamorelin stack users who prefer sustained GH bleed over daily injections.

Verdict

For clinical legitimacy, established efficacy, and physician-supervised protocols, tesamorelin is the superior choice — it is the only GHRH analog with FDA approval and randomized controlled trial evidence for specific clinical endpoints (visceral fat reduction, metabolic improvement). For anti-aging, performance, or GH optimization in research/off-label contexts, CJC-1295 (particularly the DAC form) offers practical advantages: dramatically longer half-life for less frequent dosing, sustained IGF-1 elevation, and lower cost. The optimal approach for maximizing GH release is stacking either GHRH analog with a GHRP like ipamorelin — combining CJC-1295 with ipamorelin is one of the most popular GH optimization stacks. Consult a healthcare provider familiar with peptide protocols before use.

References

  1. Tesamorelin, a synthetic GHRH analog, reduces visceral fat in HIV-infected patients (IGAB-021) (2010) — PubMed
  2. Effects of CJC-1295, a long-acting GHRH analog, on growth hormone (GH) and IGF-1 in healthy adults (2006) — PubMed
  3. Tesamorelin reduces visceral adiposity and metabolic complications in HIV lipodystrophy — Phase 3 (2010) — PubMed
  4. Sermorelin and tesamorelin: clinical applications of growth hormone-releasing hormone analogs (2013) — PubMed
  5. Growth hormone releasing peptides and their analogs: therapeutic potential (2007) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Frequently Asked Questions

What is the difference between tesamorelin and CJC-1295?
Both are GHRH analogs that stimulate natural GH release from the pituitary. Tesamorelin is a modified GHRH(1-44) analog with FDA approval for HIV lipodystrophy and well-documented clinical efficacy from Phase 3 trials. CJC-1295 is a modified GHRH(1-29) analog available with or without a Drug Affinity Complex (DAC); the DAC version has a dramatically longer half-life (~6–8 days) enabling once-weekly dosing. Tesamorelin requires daily injection; CJC-1295 DAC can be injected once or twice a week. Tesamorelin has more clinical evidence; CJC-1295 has more dosing convenience.
Can I stack tesamorelin with ipamorelin?
Yes — combining a GHRH analog (tesamorelin) with a GHRP (ipamorelin) is a standard and well-supported approach for maximizing GH release. GHRH and GHRP act on different receptors with synergistic effects — together they produce GH pulses 3–5× greater than either alone. A typical clinical protocol is 1 mg tesamorelin + 200–300 mcg ipamorelin administered together subcutaneously before bed on an empty stomach. Always consult a healthcare provider for personalized protocols.
Is CJC-1295 or tesamorelin better for fat loss?
Tesamorelin has the stronger evidence for fat loss specifically — randomized Phase 3 trials demonstrated significant visceral adipose tissue reduction in HIV patients. CJC-1295 promotes GH and IGF-1 elevation which has lipolytic effects, but this has not been studied in rigorous fat-loss-specific trials. For visceral fat reduction specifically, tesamorelin has the most direct evidence. For general body composition improvement through sustained GH elevation, CJC-1295 DAC is commonly used in research and performance contexts.
Which is safer — tesamorelin or CJC-1295?
Tesamorelin has a better-characterized safety profile from Phase 3 clinical trials and post-market surveillance. Known side effects include injection site reactions, arthralgia, edema, and potential glucose metabolism effects. CJC-1295's safety is less well-characterized in formal human studies, though it is generally considered to have a similar profile to other GHRH analogs. The CJC-1295 DAC form's sustained GH elevation means any side effects (joint pain, water retention) may persist longer. Neither is approved for general GH optimization use.
What does CJC-1295 DAC vs no DAC mean?
CJC-1295 with DAC (Drug Affinity Complex) includes a chemical modification that allows it to bind to albumin in the bloodstream, extending its half-life from ~30 minutes to approximately 6–8 days. This means one or two weekly injections instead of daily dosing. CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF 1-29) has a short half-life similar to native GHRH and requires 1–3 daily injections. The DAC form produces a more sustained GH baseline elevation; the no-DAC form produces more pulsatile GH release similar to the physiological pattern.

Explore next